Cialis Offer Up To 2.3 Billion Dollars
Written by Stuart Stevens | Monday, 18 December 2006 | There are 0 comments
Cialis is the worlds 2nd best selling erectile dysfunction drug
It seems like Eli Lilly are under pressure as they have finally agreed to pay another 200 million dollars on top of the 2.1 billion dollar offer they made for the Cialis shares belonging to ICOS. This increases the individual share price of the company to $34 up from the previous offer of $32 per share. The main motivation for the increased share price offer was that one of the biggest ICOS shareholders namely HealthCor feels that ICOS is worth more like $40 a share and was urging the management of ICOS not to accept the offer.
The ISS, an independent body that regulates and advises on corporate issues was also of the opinion that the price was too low and felt that the timing of the announcement just 2 days before big increases in sales were announced was not correct.
Eli Lilly are adamant that this offer of $34 dollars is its final and last offer and they announced that they felt that ICOS shareholders would accept this increased offer price. Sidney Taural who is the CEO of Eli Lilly was in a confident mood and talked about the ‘substantial value and the ‘certainty’ that the offer represented.
Cialis is the worlds 2nd best selling erectile dysfunction drug and some people feel that in a couple of years it may beat Viagra to the top spot. The erectile dysfunction market continues to grow all over the world and the future looks bright for any erectile dysfunction medication.
Both Eli Lilly and the management of ICOS have approved the new $34 offer but it is yet to be known what Healthcor think of the new offer and whether the final meeting in December 19th will get all shareholders on board.
Ukmedix will be keeping an eye out for any new updates to this story.
